News Sobi stays on its acquisitive streak with $915m Dova deal Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova
News NIH abandons trial of SIGA's mpox drug Another clinical trial has found that SIGA Technologies' antiviral drug TPOXX (tecovirimat) is ineffective as a treatment for mpox.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
